HC Wainwright Issues Positive Outlook for Harrow Earnings

Harrow, Inc. (NASDAQ:HROW) – Investment analysts at HC Wainwright raised their Q3 2026 earnings per share (EPS) estimates for shares of Harrow in a research report issued on Thursday, March 19th. HC Wainwright analyst Y. Chen now anticipates that the company will earn $0.21 per share for the quarter, up from their previous forecast of $0.20. HC Wainwright has a “Buy” rating and a $70.00 price target on the stock. The consensus estimate for Harrow’s current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for Harrow’s FY2026 earnings at $0.56 EPS.

Several other equities analysts have also commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Harrow in a research note on Thursday, January 22nd. BTIG Research restated a “buy” rating and set a $63.00 price target on shares of Harrow in a research note on Wednesday, March 18th. Cantor Fitzgerald decreased their price target on shares of Harrow from $94.00 to $91.00 and set an “overweight” rating for the company in a report on Wednesday, March 4th. William Blair reiterated an “outperform” rating on shares of Harrow in a research note on Tuesday, March 3rd. Finally, Zacks Research lowered shares of Harrow from a “hold” rating to a “strong sell” rating in a report on Tuesday, March 3rd. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $71.14.

Harrow Price Performance

Shares of HROW stock opened at $33.28 on Monday. Harrow has a fifty-two week low of $20.85 and a fifty-two week high of $54.85. The company has a debt-to-equity ratio of 4.67, a quick ratio of 2.06 and a current ratio of 2.20. The firm has a market capitalization of $1.24 billion, a price-to-earnings ratio of -195.75 and a beta of 0.05. The stock’s 50-day simple moving average is $44.53 and its 200-day simple moving average is $43.53.

Institutional Investors Weigh In On Harrow

A number of large investors have recently bought and sold shares of HROW. University of Texas Texas AM Investment Management Co. acquired a new position in Harrow in the 4th quarter worth approximately $26,000. SBI Securities Co. Ltd. lifted its stake in Harrow by 393.5% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,061 shares of the company’s stock valued at $52,000 after acquiring an additional 846 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Harrow in the 2nd quarter valued at $48,000. State of Alaska Department of Revenue purchased a new stake in shares of Harrow in the 3rd quarter valued at $83,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Harrow by 25.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,800 shares of the company’s stock worth $88,000 after acquiring an additional 369 shares during the period. Hedge funds and other institutional investors own 72.76% of the company’s stock.

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.